Community Initiative Curbs Pediatric Asthma

BY SUSAN LONDON
Elsevier Global Medical News

VANCOUVER, B.C. — An initiative that promotes improved asthma education and care at the family and community levels has reduced health care use and morbidity among disadvantaged children with asthma in Boston, according to Dr. Elizabeth R. Woods.

Four years into the Community Asthma Initiative, there was an 81% reduction in the percentage of participating children having asthma-related emergency department visits, a 39% reduction in the percentage of children making emergency department visits, a 39% reduction in the percentage missing days of school because of asthma, and a 37% reduction in the percentage having limitations in physical activity because of the disease, Dr. Woods said at the annual meeting of the Pediatric Academic Societies.

The initiative targeted children from the four Boston neighborhoods with the highest asthma rates and the greatest health disparities. The children and their families received case management and home visits by providers who helped them develop an individualized management plan, performed an environmental assessment, and supplied products such as vacuum cleaners with high-efficiency particulate air filters and bedding casings. Providers also instructed families in pest control techniques and connected them to community resources.

The initiative also targeted the community through an educational campaign and encouraged payers to address prohibitively high copayments for asthma medications.

Dr. Woods and her colleagues evaluated the effects of the initiative by analyzing parental reports and administrative data.

Results were based on 441 children (average age, 7.8 years) who had received case management through the initiative. Most were African American.

See Asthma • page 6

Study Backs Low-Dose Oral Steroids For Acute COPD

BY MARY ANN MOON
Elsevier Global Medical News

Low-dose oral corticosteroids are as effective as high-dose intravenous corticosteroids in the initial treatment of acute exacerbations of COPD, according to findings from a retrospective cohort study of nearly 80,000 COPD hospitalizations.

In the study, 92% of the patients were initially given high-dose IV corticosteroids instead of less-risky low-dose oral steroids. This contrasts sharply with recommendations favoring a low-dose regimen included in clinical guidelines published by leading professional societies in the United States, the United Kingdom, and other European nations, said Dr. Peter K. Lindenauer of the Center for Quality of Care Research at Baystate Medical Center, Springfield, Mass., and his associates.

Dr. Lindenauer and his colleagues compared outcomes with these two treatment approaches using a database designed to measure health care quality and utilization. They reviewed the records of 79,985 hospitalizations for acute exacerbation of COPD at 414 U.S. medical centers over a 2-year period.

The study participants had a median age of 69 years and had COPD that was uncomplicated by pneumonia or pulmonary embolism. The primary outcome was a composite measure of treatment failure, defined as the need for mechanical ventilation after the second day of hospitalization, death during hospitalization, or readmission for COPD within 30 days of discharge.

Overall, 11% of patients had this primary outcome, with approximately 1% requiring steroid therapy.

See Steroids • page 3

Novel OSA Agents in Pipeline

BY BRUCE JANCIN
Elsevier Global Medical News

SAN ANTONIO — Although obstructive sleep apnea is closely associated with obesity, not all the drugs being developed for the treatment of OSA are based on weight loss as their mechanism of benefit.

For example, acetazolamide addresses ventilatory instability, which has emerged as a potential novel therapeutic target in OSA. Another early study suggests the sedative eszopiclone (Lunesta) reduces sleep apnea severity and increases sleep duration by raising the respiratory arousal threshold, investigators reported at the annual meeting of the Associated Professional Sleep Societies.

Still, weight loss is the classic source of pharmacologic improvement in OSA. The first drug shown to be of benefit in OSA patients was sibutramine (Meridia), a serotonin and norepinephrine reuptake inhibitor, noted Dr. Ronald R. Grunstein, professor of sleep medicine at the University of Sydney.

He was lead investigator in a study of nearly 80,000 patients.
Pandemic Flu Reassortment Could Pose New Threat

BY DENISE NAPOLI
Elsevier Global Medical News

Researchers are warning that the pandemic 2009 H1N1 influenza strain has been combining with other influenza strains among Hong Kong swine, and that further vi-
ral reassortment among global swine populations could again cause a pandemic in humans.

“The 2009 pandemic, although mild and apparently contained at present, could undergo further reassortment in swine and gain virulence,” wrote Dr. Dhanasekaran Vijaykrishna and associates at the State Key Lab-
oratory of Emerging Infectious Diseases at the University of Hong Kong. The investigators called for greater surveillance in swine and recommended “that all eight gene segments are genetical-
ically characterized so that such reassortment events are rapidly identified.”

In their study, Dr. Vijaykrish-
na and colleagues looked at tracheal and nasal swab samples taken from swine at a Hong Kong slaughterhouse between June 11, 2009, and Feb. 4, 2010. Samples were taken every 2 weeks on up to 252 swine per
sampling occurrence, for a total of 4,101 samples of unique swine. Overall, H1N1 and H1N2 viruses were isolated from 32 samples (Science 2010;328:1529).

Pandemic flu viruses “isolated on the same sampling occasion were genetically identical, sug-
gesting transmission of viruses occurred within swine herds,” the researchers said.

However, “viruses from dif-
ferent sampling dates were ge-
netically distinct from each other and also from (2009 H1N1)-like swine viruses isolated in other countries, indicating multiple independent introductions of these viruses from humans to swine,” they said.

But the greatest concern comes from a January 2010 sam-
ping where a novel reassortant was discovered; the new strain was named A/swine/Hong Kong/201/2010 (H1N1). This novel strain—with a hemagglut-
inin gene most closely resembling European avian-based influenzas and a neuraminidase gene likely derived from the 2009 swine-derived H1N1 strain—could be particularly contagious.

Neither the 2009 H1N1 vaccine nor natural infection reliably elicits cross-protective
antibody to A/swine/Hong Kong/201/2010,” they wrote.

Further laboratory testing of the new strain revealed that while the virus was susceptible to oseltamivir, it was resistant to adamantanes. Viral shedding oc-
curred among the infected swine for up to 13 days.

“The introduction of [pan-
demic H1N1] virus to swine has provided it with opportunities for reassortment,” Dr. Vijay-
krishna and coworkers wrote. This “reservoir of reassortment” could, if left unchecked, “pro-
duce new viruses of potential threat to public health.”

Weight Loss Not Only Target

OSA • from page 1

study that showed 6 months of sibu-
tramine plus diet and exercise not only resulted in significant weight loss, ... is available on the Web at www.chestnet.org/accp/chester-physician/01_6ch10_7.qxp 7/8/2010 4:36 PM Page 2

CHEST Physician is Online
CHEST PHYSICIAN is available on the Web at www.chestnet.org/accp/chester-physician.

HDL, cholesterol, and decreased visceral, subcutaneous, and hepatic fat, with no change in blood pressure (J. Clin. Sleep Med. 2009;5:416-21).

At the sleep disorders meeting, audi-
cences learned of another new drug with evidence of efficacy for OSA: Qnexa, an investigational once-daily pro-
prietary combination of phentermine and controlled-release topiramate.

Dr. David H. Winslow presented a double-blind, single-center trial in which 45 obese patients with OSA were ran-
donized to once-daily Qnexa at 15-mg phenertmine/92-mg topiramate CR or to placebo for 28 weeks. At week 8, the mean apnea-hypopnea index (AHI) in the Qnexa group had dropped from a baseline of 45.5 to 19.1 events per hour. By week 28, their mean AHI had fallen to 13.5, compared with 27.2 in the placebo arm, reported Dr. Winslow, a chest physician and president of the Ken-
tucky Research Group, Lexington.

The Qnexa group experienced a mean 11% reduction in body weight over the 28 weeks, twice that of the placebo group. Other statistically significant changes in the Qnexa group included a mean 15-mm Hg drop in systolic blood pressure from a baseline of 138 mm Hg, compared with a 7.3-mm Hg drop in con-
trols, along with improvements in arousal indices and overnight oxygen saturation.

“I think we may be looking at a new paradigm in the treatment of OSA,” Dr. Winslow said in an interview. Qnexa is under Food and Drug Administration re-
view for a proposed indication as a treat-
ment for obesity; a regulatory decision is expected later this year.

Danny J. Eckert, Ph.D., of Brigham and Women’s Hospital, Boston, present-
ed a double-blind, randomized, crossover trial in which 17 untreated OSA patients received 3 mg of eszopiclone or placebo immediately prior to going to sleep dur-
ing overnight polysomnography on two occasions, one with and one without CPAP. The patients’ mean AHI was 24 events per hour on eszopiclone, compared with 31 per hour with placebo. Patients on eszopiclone also had a marked increase in total sleep time, from 5.3 hours on placebo to 6.8 hours, along with fewer arousals per hour and improved sleep quality, he reported.

Dr. Bradley A. Edwards, also of Brigham and Women’s Hospital, pre-
sented a preliminary physiologic study in which six CPAP-treated patients with OSA underwent 7 nights of baseline polysomnography, and then took aceta-
zolamide SR 300 mg twice daily for a week. This was followed by another 2 nights of polysomnography in which CPAP was intermittently turned down to subtherapeutic levels in order to see whether acetazolamide reduced ventilatory control instability. This indeed proved to be the case in all six patients. Moreover, five of the six patients expe-
rrienced an associated reduction in AHI.

Dr. Winslow disclosed serving as a consultant to Vivus, which is developing Qnexa. Dr. Eckert’s study was partly funded by a research grant from Separa-
cor. Dr. Grunstein’s study was supported by Abbott Laboratories. Dr. Edwards reported no financial conflicts.
Low Dose as Effective
Steroids • from page 1

mechanical ventilation, 1% dying during hospitalization, and 9% being readmitted.

A total of 92% of patients were initially treated with high-dose IV steroids and 8% were started on oral steroids. The composite outcome of treatment failure occurred in 10.9% of patients given high-dose IV steroids and 10.3% of those given low-dose oral steroids, a nonsignificant difference. Similarly, the individual outcome of in-hospital mortality was approximately 1% in both groups, they said (JAMA 2010;303:2359-67).

Further analysis showed that patients given oral steroids as recommended had lower hospital costs and shorter lengths of stay. Previous studies of the issue have shown that the oral route decreases patient pain and immobility, they added.

The findings clearly show that not complying with treatment recommendations and instead giving high-dose IV steroids to patients with acute exacerbations of COPD “does not appear to be associated with any measurable clinical benefit and at the same time exposes patients to the risks and inconvenience of an intravenous line, potentially unnecessarily high doses of steroids, greater hospital costs, and longer lengths of stay,” Dr. Lindenauer and his associates said.

“Because high-dose IV therapy is so common and because patients with COPD are hospitalized frequently for exacerbations, our findings have a significant potential to alter practice,” they added.

Low Dose of Corticosteroids

Dr. Nicola A. Hanania, FCCP, comments: The use of systemic corticosteroids in the management of acute exacerbations of COPD is essential and has been shown to affect clinical outcomes and rates of relapse of exacerbations. It is not known, however, whether intravenous high-dose corticosteroids are superior to lower-dose oral corticosteroids. This report is based on an observational, retrospective analysis of a large database suggesting that both methods of administration are associated with similar outcomes. Similar observations have been described in the management of acute asthma, as well.

However, because much of such a study may be associated with selection and treatment allocation bias, one cannot draw firm conclusions. Prospective studies to confirm these findings are needed.
temp: 101.9°F  
O₂ sat: 89%  
WBC: 18.1  
MRSA  
nosocomial pneumonia  
PMNs: 80%, bands: 15%  
creatinine: 2.6  
CXR: LLL infiltrate
Some patients have ZYVOX written all over them

With proven efficacy, excellent tissue penetration, and clear and consistent dosing, count on ZYVOX to treat MRSA in patients with nosocomial pneumonia whose conditions are complicated by renal insufficiency.1-3

— Please see www.zyvox.com for further information

ZYVOX is indicated in the treatment of the following infections caused by susceptible strains of the designated microorganisms:

Nosocomial pneumonia caused by Staphylococcus aureus (methicillin-susceptible and -resistant strains) or Streptococcus pneumoniae (including multidrug-resistant strains [MDRSP]).

Complicated skin and skin structure infections, including diabetic foot infections, without concomitant osteomyelitis, caused by Staphylococcus aureus (methicillin-susceptible and -resistant strains), Streptococcus pyogenes, or Streptococcus agalactiae. ZYVOX has not been studied in the treatment of decubitus ulcers.

ZYVOX use is contraindicated in patients with known hypersensitivity to linezolid or any of the other product components.

ZYVOX should not be used in patients taking any medicinal product which inhibits monoamine oxidases A or B (e.g. phenelzine, isocarboxazid) or within 2 weeks of taking any such product.

Unless patients are monitored for potential increases in blood pressure, ZYVOX should not be administered to patients with uncontrolled hypertension, pheochromocytoma, thyrotoxicosis and/or patients taking any of the following: directly and indirectly acting sympathomimetic, vasopressive, and dopaminergic agents.

Unless patients are carefully observed for signs and/or symptoms of serotonin syndrome, ZYVOX should not be administered to patients with carcinoid syndrome and/or patients taking any of the following medications: serotonin reuptake inhibitors, tricyclic antidepressants, serotonin 5-HT1 receptor agonists, meperidine, or buspirone.

Spontaneous reports of serotonin syndrome have been reported with the coadministration of ZYVOX and serotoninergic agents. If signs or symptoms of serotonin syndrome, such as cognitive dysfunction, hyperpyrexia, hyperreflexia, and incoordination occur, discontinuation of one or both agents should be considered.

Myelosuppression (including anemia, leukopenia, pancytopenia, and thrombocytopenia) has been reported in patients receiving ZYVOX. In cases where the outcome is known, when ZYVOX was discontinued, the affected hematologic parameters returned to pretreatment levels. Complete blood counts should be monitored weekly, particularly in patients who receive ZYVOX for longer than 2 weeks.

ZYVOX is not approved and should not be used for the treatment of patients with catheter-related bloodstream infections or catheter-site infections.

ZYVOX has no clinical activity against Gram-negative pathogens and is not indicated for the treatment of Gram-negative infections. It is critical that specific Gram-negative therapy be initiated immediately if a concomitant Gram-negative pathogen is documented or suspected.

Clostridium difficile associated diarrhea has been reported with use of nearly all antibacterial agents, including ZYVOX, and may range in severity from mild diarrhea to fatal colitis.

Lactic acidosis has been reported with the use of ZYVOX. Patients receiving ZYVOX who develop recurrent nausea, vomiting, unexplained acidosis, or a low bicarbonate level should receive immediate medical evaluation.

Peripheral and optic neuropathy have been reported primarily in patients treated with ZYVOX for longer than the maximum recommended duration of 28 days. If patients experience symptoms of visual impairment, prompt ophthalmic evaluation is recommended.

Convulsions have been reported in patients treated with ZYVOX. In some of these cases, a history of seizures or risk factors for seizures was reported.

The most commonly reported adverse events in adults across phase 3 clinical trials were diarrhea, nausea, and headache.


Please see brief summary on adjacent pages.
between baseline and 12 months, the proportion of children making asthma-related emergency department visits fell from 63% to 22%, hospital admissions due to asthma fell from 51% to 10%, and the proportion of children who missed days of school because of asthma dropped from 93% to 56%. In addition, the proportion of children who had physical activity limitations due to asthma dropped by 71% (from 49% to 48%).

Between baseline and 12 months, the proportion of children making asthma-related emergency department visits fell from 63% to 22%, hospital admissions due to asthma fell from 51% to 10%, and the proportion of children who missed days of school because of asthma dropped from 93% to 56%. In addition, the proportion of children who had physical activity limitations due to asthma dropped by 71% (from 49% to 48%).

In logistic regression analyses controlling for potential confounders, the children had significant 90%-100% reductions in the odds of each adverse outcome, noted Dr. Woods, a pediatrician at Children's Hospital Boston.

In the first year of the initiative, the cost of care per child was similar to that in a control neighborhood ($1,335 vs. $1,340). In the second year, it was approximately half as expensive in the initiative group ($750 vs. $1,322).

Dr. Woods noted that the initiative supported helping families in two important ways: understanding medications and addressing environmental issues. ‘Very few of these families had even a vacuum cleaner, let alone ones with HEPA bags,” she said. “These are incredibly expensive and much less costly than additional medication,” she added.

In logistic regression analyses controlling for potential confounders, the children had significant 90%-100% reductions in the odds of each adverse outcome, noted Dr. Woods, a pediatrician at Children's Hospital Boston. In the first year of the initiative, the cost of care per child was similar to that in a control neighborhood ($1,335 vs. $1,340). In the second year, it was approximately half as expensive in the initiative group ($750 vs. $1,322). Dr. Woods noted that the initiative supported helping families in two important ways: understanding medications and addressing environmental issues. ‘Very few of these families had even a vacuum cleaner, let alone ones with HEPA bags,” she said. “These are incredibly expensive and much less costly than additional medication,” she added.

In the first year of the initiative, the cost of care per child was similar to that in a control neighborhood ($1,335 vs. $1,340). In the second year, it was approximately half as expensive in the initiative group ($750 vs. $1,322). Dr. Woods noted that the initiative supported helping families in two important ways: understanding medications and addressing environmental issues. ‘Very few of these families had even a vacuum cleaner, let alone ones with HEPA bags,” she said. “These are incredibly expensive and much less costly than additional medication,” she added.

In the first year of the initiative, the cost of care per child was similar to that in a control neighborhood ($1,335 vs. $1,340). In the second year, it was approximately half as expensive in the initiative group ($750 vs. $1,322). Dr. Woods noted that the initiative supported helping families in two important ways: understanding medications and addressing environmental issues. ‘Very few of these families had even a vacuum cleaner, let alone ones with HEPA bags,” she said. “These are incredibly expensive and much less costly than additional medication,” she added.

In the first year of the initiative, the cost of care per child was similar to that in a control neighborhood ($1,335 vs. $1,340). In the second year, it was approximately half as expensive in the initiative group ($750 vs. $1,322). Dr. Woods noted that the initiative supported helping families in two important ways: understanding medications and addressing environmental issues. ‘Very few of these families had even a vacuum cleaner, let alone ones with HEPA bags,” she said. “These are incredibly expensive and much less costly than additional medication,” she added.

In the first year of the initiative, the cost of care per child was similar to that in a control neighborhood ($1,335 vs. $1,340). In the second year, it was approximately half as expensive in the initiative group ($750 vs. $1,322). Dr. Woods noted that the initiative supported helping families in two important ways: understanding medications and addressing environmental issues. ‘Very few of these families had even a vacuum cleaner, let alone ones with HEPA bags,” she said. “These are incredibly expensive and much less costly than additional medication,” she added.

In the first year of the initiative, the cost of care per child was similar to that in a control neighborhood ($1,335 vs. $1,340). In the second year, it was approximately half as expensive in the initiative group ($750 vs. $1,322). Dr. Woods noted that the initiative supported helping families in two important ways: understanding medications and addressing environmental issues. ‘Very few of these families had even a vacuum cleaner, let alone ones with HEPA bags,” she said. “These are incredibly expensive and much less costly than additional medication,” she added.

In the first year of the initiative, the cost of care per child was similar to that in a control neighborhood ($1,335 vs. $1,340). In the second year, it was approximately half as expensive in the initiative group ($750 vs. $1,322). Dr. Woods noted that the initiative supported helping families in two important ways: understanding medications and addressing environmental issues. ‘Very few of these families had even a vacuum cleaner, let alone ones with HEPA bags,” she said. “These are incredibly expensive and much less costly than additional medication,” she added.

In the first year of the initiative, the cost of care per child was similar to that in a control neighborhood ($1,335 vs. $1,340). In the second year, it was approximately half as expensive in the initiative group ($750 vs. $1,322). Dr. Woods noted that the initiative supported helping families in two important ways: understanding medications and addressing environmental issues. ‘Very few of these families had even a vacuum cleaner, let alone ones with HEPA bags,” she said. “These are incredibly expensive and much less costly than additional medication,” she added.

In the first year of the initiative, the cost of care per child was similar to that in a control neighborhood ($1,335 vs. $1,340). In the second year, it was approximately half as expensive in the initiative group ($750 vs. $1,322). Dr. Woods noted that the initiative supported helping families in two important ways: understanding medications and addressing environmental issues. ‘Very few of these families had even a vacuum cleaner, let alone ones with HEPA bags,” she said. “These are incredibly expensive and much less costly than additional medication,” she added.

In the first year of the initiative, the cost of care per child was similar to that in a control neighborhood ($1,335 vs. $1,340). In the second year, it was approximately half as expensive in the initiative group ($750 vs. $1,322). Dr. Woods noted that the initiative supported helping families in two important ways: understanding medications and addressing environmental issues. ‘Very few of these families had even a vacuum cleaner, let alone ones with HEPA bags,” she said. “These are incredibly expensive and much less costly than additional medication,” she added.

In the first year of the initiative, the cost of care per child was similar to that in a control neighborhood ($1,335 vs. $1,340). In the second year, it was approximately half as expensive in the initiative group ($750 vs. $1,322). Dr. Woods noted that the initiative supported helping families in two important ways: understanding medications and addressing environmental issues. ‘Very few of these families had even a vacuum cleaner, let alone ones with HEPA bags,” she said. “These are incredibly expensive and much less costly than additional medication,” she added.

In the first year of the initiative, the cost of care per child was similar to that in a control neighborhood ($1,335 vs. $1,340). In the second year, it was approximately half as expensive in the initiative group ($750 vs. $1,322). Dr. Woods noted that the initiative supported helping families in two important ways: understanding medications and addressing environmental issues. ‘Very few of these families had even a vacuum cleaner, let alone ones with HEPA bags,” she said. “These are incredibly expensive and much less costly than additional medication,” she added.

In the first year of the initiative, the cost of care per child was similar to that in a control neighborhood ($1,335 vs. $1,340). In the second year, it was approximately half as expensive in the initiative group ($750 vs. $1,322). Dr. Woods noted that the initiative supported helping families in two important ways: understanding medications and addressing environmental issues. ‘Very few of these families had even a vacuum cleaner, let alone ones with HEPA bags,” she said. “These are incredibly expensive and much less costly than additional medication,” she added.
Selenium Failed to Prevent Second Lung Cancers

BY JANE SALODOF MAC NEILE
Elsevier Global Medical News

CHICAGO — Selenium supplementation does not prevent second cancers in survivors of early-stage lung cancer—and may even make these patients more vulnerable to new tumors.

Indeed, although the differences did not reach statistical significance, patients who used supplements developed more second cancers, including lung tumors, than those who did not take selenium in a randomized, controlled phase III chemoprevention trial that was stopped early for futility.

“Dr. Karp can say for sure that the selenium was not beneficial,” Dr. Daniel Karp said at the annual meeting of the American Society of Clinical Oncology, where he presented data on 1,522 patients who had been randomized from October 2000 to November 2009 and followed for a median of more than 4 years.

As of August 2009, the trial population had developed 216 second primary tumors, including 84 new lung cancers in 83 patients (one patient had two new lung tumors). The incidence of second primary tumors of any type after 1 year was 4.13% in the selenium cohort and 3.66% among those not given supplementation.

The progression-free survival rate at 5 years was also slightly better in the placebo group (78% vs. 72%), as was overall survival at 3 years (90% vs. 85%) and 5 years (80% vs. 75%).

The Eastern Cooperative Oncology Group (ECOG) started the intergroup trial after a study that failed to show selenium could prevent skin cancers suggested that it could reduce the incidence of lung, colorectal, and prostate cancers by as much as 30% (JAMA 1996;276:1957-63). The ECOG trial enrolled patients 6-36 months after complete resection of stage 1 non-small cell lung cancer. All had no sign of disease on biopsy.

Randomization was 3:1 to 200 mcg daily of selenium yeast for 4 years or placebo. Most patients had normal selenium levels when they entered the trial, said Dr. Karp, a professor of thoracic/head and neck medical oncology at the University of Texas M.D. Anderson Cancer Center in Houston.

 Particularly concerning, he noted, was that the amount of selenium in the supplement used in the trial is comparable to the amount in most daily multivitamins.

“People need to find people who are deficient and make sure they have a normal amount,” he said, questioning the wisdom of giving supplements to everyone.

One possibility Dr. Karp suggested in a press briefing is that antioxidants might have a harmful effect in the presence of carcinogens such as tobacco. Another study found worse outcomes—higher incidence of lung cancer and risk of death from the disease—in people who took beta-carotene (N. Engl. J. Med. 1996;334:1150-5).

Dr. Karp disclosed receiving research funding from Pfizer.

Dr. W. Michael Alberts, FCCP, comments: This study presents out the potential danger of supplements. Not only did supplemental selenium fail to prevent second lung cancer, but those in the active arm actually developed more second cancers. The latter did not reach statistical significance, but the point is made. Supplements are not necessarily beneficial—and may be harmful.
Sleep Apnea and Trucking: On the Road to Health and Safety

The American Sleep Apnea Association (ASAA) organized and presented the Sleep Apnea Trucking Conference 2010 (SACT 2010) this May in Baltimore, MD. The conference was cosponsored by the Federal Motor Carrier Safety Administration (FMCSA) and American Trucking Associations (ATA). This day-long program brought together major stakeholders concerned with public policy issues for obstructive sleep apnea (OSA) and the commercial motor vehicle (CMV) driver in an effort to increase awareness, present current programs and research in development, and stimulate forward thinking to work together on this public health issue.

The speakers, and over 400 audience members, included those from governmental agencies (regulatory and advisory), professional truckers (Owner Operator Independent Drivers Association [OOIDA] and major trucking firms), sleep apnea management programs, and the medical community (sleep and occupational medicine). The American College of Chest Physicians (ACCP) was one of many additional supporters. The program was preceded by an evening reception with welcome by Edward Grandi, Executive Director of ASAA, and Mark Berger of Precision Pulmonary Diagnostics. Speakers included Anne Ferro, FMCSA Administrator; Christopher Hart, Vice-Chairman of the National Transportation Safety Board (NTSB); and Jeffrey Burns, Esq., who served several organizations for improved highway safety, including the Truck Safety Coalition.

**Meeting Highlights**

Dr Mary Gannels (FMCSA Office of Medical Programs) emphasized the large task assignment (400,000 medical examinations monthly) targeted by future regulations. There is increasing awareness of the relationship of obesity and general health concerns, as well as the increase for the risk for OSA. Sleep apnea and sleep disorders are sources for fatigue, and fatigue has been identified as a cause of motor vehicle crashes. The upcoming national registry for OSA will include new language and education about sleep apnea.

Dr Martin Walker (FMCSA Chief of Research) reviewed data published May 2002 on the prevalence of OSA in CMV drivers of 28% (17.6% mild, 5.8% moderate, 4.7% severe), with increases noted with age and body mass index (BMI), as well as 6 or fewer hours of sleep. Severe OSA is associated with increased risk of severe crashes in CMV drivers.

Dr Weller questioned the current status of OSA diagnosis and treatment availability and adherence, and he called for better screening tools, more research on OSA with crash risk, low cost validated testing, determinants of compliance, and better outreach regarding health and safety issues. He presented information about the campaign, “Get on the Road to Better Health: Recognizing the Dangers of Sleep Apnea,” by the National Sleep Foundation and FMCSA. He discussed the FMCSA request for proposals for a Commercial Driver Individual Differences Study (CDIDS), studying 11,000 CMV drivers to identify 1,000 cases (crash within the last 3 yr) and 3,000 controls assessing driver factors with high risk for crashes, and a sub-study of 1,200 undiagnosed drivers at risk for OSA for undertaking testing and treatment to develop a cost effective approach and evaluate linkage to crash risk.

Public health issues, linked to the Department of Health and Human Services Healthy People 2020 (www.healthypeople.gov/1HP2020), were discussed by Dr Karl Sieber (National Institute for Occupational Safety and Health - NIOSH). He indicated that the increased prevalence for OSA appears to be associated with decreased crashes and stressed importance of monitoring for insufficient sleep. He reviewed a cross-sectional survey studying long haul (trucker, driver, conducted at a CMV stop) truck stops nationally, including health-related scales, such as the Trucker Sleep Monitor scale (De Cron et al. Int Arch Environ Health. 2001;74[6]: 429-437). The item scale varied from a professional driver and one diagnosed with sleep apnea. While fully supportive of the importance of diagnosis and treatment, he raised a number of unique challenges for even the compliant trucker using CPAP on the road and in the cab of the truck. He also shared his concerns about the risk to livelihood for those without large industry support making diagnosis and treatment.

Several representatives from various sleep apnea management programs outlined methods of enhancing availability for diagnosis and treatment for those living on the road. The program concluded with speakers for Schneider National (Don Osterberg) and JB Hunt (Debra Plumlee) who have successfully incorporated such programs into their organizations. Robert Wursham spoke on behalf of OOIDA and presented the particular challenges facing the individual owner-operator trucker who may not have the safety net of industry support, along with risks of diagnosis, treatment, and risk to livelihood of out of service time following the diagnosis.

In summary, the association of OSA, fatigue, and crash risk is largely accepted, but its magnitude within the trucking industry and the solution to the problem remain challenged. The Sleep Apnea and Trucking Conference raised many issues regarding sleep and appropriate health care for truck drivers. Who is responsible for clarifying the rules for identification of at-risk truckers? Who will cover the costs of screening programs, diagnosis, and related treatment? Who is responsible for monitoring compliance and ultimate medical clearance? As truck drivers are mobile and can be traveling for weeks at a time, there are unique challenges with access to testing and treatment facilities. Other acknowledged concerns include limited treatment options with CPAP as the only acceptable noninvasive therapy, documentation of adherence, and guidelines on how much adherence is adequate and the relationship of fatigue in the workplace and accident risk reduction. How do all of these issues affect the industry-employed vs independent owner-operator trucker? Besides the public health and safety risk issues, there remain individual concerns regarding employment risk.

Unfortunately, many of the logistic questions seemed to override the concern for the individual’s health and safety.

While there were no major decisions reached, there was general consensus that more dialogue is needed. While the regulatory bodies plan a continued search for objective data for future decision making, the response to the audience concerns for current definitive language. The audience was promised a new regulatory document in the making, with a call for better guidelines, more defined statements, and a clearer path to diagnosis and treatment.

Many voiced the need to “do this again,” focusing on sleep-related health of the professional driver (trucker, bus driver, and others with a commercial drivers license). However, with a majority of Americans getting inadequate sleep, drowsy driving issues extend far greater than just sleep apnea in the professional driver market, and more policies will hopefully reflect these high-risk health and safety issues. Additional information and links on this topic are available at the official SACT 2010 Web site, www.sact2010.org.
Background
In the United States, four different national organizations support and represent critical care professionals: the American Association of Critical-Care Nurses (AACN), the American College of Chest Physicians (ACCP), the American Thoracic Society (ATS), and the Society of Critical Care Medicine (SCCM). Several other professional societies, including the American Society of Anesthesiologists, American Academy of Pediatrics, American College of Emergency Physicians, American College of Surgeons, Society of Hospital Medicine, American Association for the Surgery of Trauma, American Burn Association, American Heart Association, and the Society for Academic Emergency Medicine, have segments devoted to critical care.

The AACN, ACCP, ATS, and SCCM have a combined membership of over 100,000 professionals. Although these organizations all cater to the needs of critical care professionals, there was some competition among the groups in the past, resulting in duplication of efforts in areas where cooperation would have been preferred. However, in recent years, these organizations have established a partnership and an ongoing dialogue, and, consequently, their efforts have been more cooperative and unified.

What’s in a name?
Although the four societies worked together on several issues and projects, their cooperative efforts were not formalized until around the year 2000. The four societies, fondly referred to as the “quad societies,” strove toward a common goal of “societies working together in collaboration for the advancement of critical care.” In 2009, the partnership was renamed the “Critical Care Societies Collaborative” (CCSC) to better reflect the spirit of collaboration. Occasionally, one organization may decline to participate on a project if it feels that the issue is not relevant to its members. Sometimes, one organization may independently initiate a project, but the others may then endorse the project. Ultimately, the CCSC has many accomplishments to its credit that demonstrate the power of partnership.

How does the collaborative function?
The CCSC members convene at the annual meetings of the SCCM and ACCP. Since the ATS and AACN meetings overlap, traditionally, the CCSC has not met at these meetings. Since 2008, because of many emerging issues requiring more attention, formal 1- to 2-day retreats have been organized annually. Agenda items that have relevance to the four organizations are identified and discussed in detail at the annual retreat.

How is this helpful to the membership?
Some of the key achievements and projects resulting from these collaborative efforts, even prior to the formation of the CCSC, are described below:

- Committee on Manpower for Pulmonary and Critical Care Societies (COMPACCS), 2000: Workforce study conducted by ATS, ACCP, SCCM, and the Association of Pulmonary and Critical Care Medicine Program Directors


- Framing Options for Critical Care in the United States (FOCCUS), 2003: A task force formed by the AACN, ACCP, ATS, and SCCM discussed how critical care is delivered in the United States and by whom. It provided recommendations addressing the critical care workforce shortage and the quality of critical care delivery (Kelley MA, et al. Chest. 2004;125[4]:1514-1517).

- AACN Standards for Establishing and Sustaining Healthy Work Environments, 2005: Release of these Standards by the AACN, with endorsement by the other societies.

- Prioritizing the Organization and Management of Intensive Care Services in the United States (ProOMIS), 2007: A consensus conference of identified stakeholders of critical care services in the United States was organized to address the perceived problems and potential solutions for delivery of critical care services (Barnato AE, et al. Crit Care Med. 2007;35[4]:1003-1011).

Continued on following page
CHEST Abstracts Delivered To You. Wherever You Are.

Monthly CHEST Current Issue abstracts and weekly CHEST Papers in Press abstracts are now available for delivery to your Kindle™ e-reader.

Current Issue feed provides the table of contents list and abstracts ahead of the print issue. Papers in Press feed offers weekly access to the abstracts of just-accepted original research to be published in CHEST. Full-text articles not available.

Try it free for 2 weeks. Subscribe for a $1.99 monthly fee (per feed).

Current Issue: www.amazon.com/gp/product/B003M5H184
Papers in Press: www.amazon.com/gp/product/B003M5H15C

THE CRITICAL CARE SOCIETIES COLLABORATIVE HAS MANY ACCOMPLISHMENTS TO ITS CREDIT THAT DEMONSTRATE THE POWER OF PARTNERSHIP

2008
Agenda items relevant to the four societies were identified. The areas discussed included the following: hospital-acquired infections; patient safety issues; evidence for critical care practices; new models of care; collaborative opportunities with other organizations, including federal agencies, related organizations, and international professional organizations; and educational joint programs. Along with the National Association for Medical Direction of Respiratory Care (NAMDRC), the Hospital-Acquired Infections Collaborative (HAI-C) was established to address patient safety issues specifically related to hospital-acquired infections. The Patient Focused Critical Care Enhancement Act – 2007: Drafted by ACCP and ATS and supported by the CCSC, was introduced in the Senate by Senators Richard Durbin (D-IL) and Mike Crapo (R-ID) and in the House by Representatives Jan Schakowsky (D-IL) and Eric Cantor (R-VA). It was reintroduced in 2009 by Senators Crapo and Sheldon Whitehouse (D-RI) and Representatives Schakowsky and Cantor.

2009
The 2009 retreat resulted in four key accomplishments:
1. A joint open letter to President Obama addressing physician involvement in end-of-life care.
2. Formal name change to the Critical Care Societies Collaborative to more accurately reflect the partnership.
3. A meeting with Dr Don Wright, then the Principal Deputy Assistant Secretary for the Department of Health and Human Services, regarding hospital-acquired infections. In an effort to improve hospital-acquired infection rates, the CCSC submitted three project proposals to HHS, of which one was approved. Currently, with AACN taking the lead, the CCSC is developing a National Awards Program to recognize achievement in the elimination of health-care-associated infections. The CCSC met again with Dr Wright in 2010 to develop further strategies to decrease health-care-associated infections.
4. Decision to share any issues of concern with the collaborative when any society is asked to endorse documents, guidelines, or position papers, or is invited to be part of another entity to partner in areas of common interest. Generally, invitations to collaborate are addressed individually to all of the CCSC organizations from these outside entities.

2010: Current Updates

Task Force for Critical Care Research: Starting in early 2009, the CCSC convened with the NIH US Critical Illness and Injury Trials Group (USCITTG) to develop a comprehensive agenda for critical care research. A multisociety Strategic Planning Task Force for Critical Care Research was formed whose goal was to define a broad, comprehensive agenda for critical care research. This agenda will serve as a blueprint for future critical care initiatives undertaken by individual investigators and targeted requests for applications issued by foundations, NIH, and other interested groups.

Five areas of research were identified: basic science, clinical, education, translational, and outcomes. The conference document is expected to include a description of the process; an outline of the background information, including research accomplishments and opportunities used by the working groups; and a prioritized list of recommendations for research areas.

Tele-ICU Study and Consensus Conference: A multicenter survey of tele-ICU interventions was performed by the ACCP Critical Care Institute. Subsequently, the Agency for Healthcare Research and Quality funded a conference to develop a consensus statement on the research agenda for ICU telemedicine. This conference was held in March of this year and was attended by an interdisciplinary group representing the four organizations of the CCSC and users of tele-ICUs around the country. The results of this conference will be published as a multisociety consensus statement and will serve to inform potential future requests for applications/proposals on the part of grant-funding agencies. The statement, which is currently being drafted by the writing committee, will be reviewed and approved by all conference participants.

Conclusion
Critical care professionals comprise a group of people with diverse backgrounds but with a common goal of improving care of the critically ill patient. By working together through the Critical Care Societies Collaborative, great strides are being made toward that goal. Continued collaboration in the future will lead to even greater improvements in the field of critical care.

This Month in CHEST: Editor’s Picks

BY DR RICHARD S. IRWIN, MASTER FCCP
Editor in Chief, CHEST

Factors Associated With Illness Perception Among Critically Ill Patients and Survivors
By Dr D. Ford, FCCP, et al.

Risk of COPD From Exposure to Biomass Smoke: A Metaanalysis
By Dr G. Hu, et al.

CHEST Abstracts Delivered To You. Wherever You Are.

Monthly CHEST Current Issue abstracts and weekly CHEST Papers in Press abstracts are now available for delivery to your Kindle™ e-reader.

Current Issue feed provides the table of contents list and abstracts ahead of the print issue. Papers in Press feed offers weekly access to the abstracts of just-accepted original research to be published in CHEST. Full-text articles not available.

Try it free for 2 weeks. Subscribe for a $1.99 monthly fee (per feed).

Current Issue: www.amazon.com/gp/product/B003MSH184
Papers in Press: www.amazon.com/gp/product/B003M5H15C

This Month in CHEST: Editor’s Picks

BY DR RICHARD S. IRWIN, MASTER FCCP
Editor in Chief, CHEST

Factors Associated With Illness Perception Among Critically Ill Patients and Survivors
By Dr D. Ford, FCCP, et al.

Risk of COPD From Exposure to Biomass Smoke: A Metaanalysis
By Dr G. Hu, et al.

CHEST Abstracts Delivered To You. Wherever You Are.

Monthly CHEST Current Issue abstracts and weekly CHEST Papers in Press abstracts are now available for delivery to your Kindle™ e-reader.

Current Issue feed provides the table of contents list and abstracts ahead of the print issue. Papers in Press feed offers weekly access to the abstracts of just-accepted original research to be published in CHEST. Full-text articles not available.

Try it free for 2 weeks. Subscribe for a $1.99 monthly fee (per feed).

Current Issue: www.amazon.com/gp/product/B003MSH184
Papers in Press: www.amazon.com/gp/product/B003M5H15C

This Month in CHEST: Editor’s Picks

BY DR RICHARD S. IRWIN, MASTER FCCP
Editor in Chief, CHEST

Factors Associated With Illness Perception Among Critically Ill Patients and Survivors
By Dr D. Ford, FCCP, et al.

Risk of COPD From Exposure to Biomass Smoke: A Metaanalysis
By Dr G. Hu, et al.

CHEST Abstracts Delivered To You. Wherever You Are.

Monthly CHEST Current Issue abstracts and weekly CHEST Papers in Press abstracts are now available for delivery to your Kindle™ e-reader.

Current Issue feed provides the table of contents list and abstracts ahead of the print issue. Papers in Press feed offers weekly access to the abstracts of just-accepted original research to be published in CHEST. Full-text articles not available.

Try it free for 2 weeks. Subscribe for a $1.99 monthly fee (per feed).

Current Issue: www.amazon.com/gp/product/B003MSH184
Papers in Press: www.amazon.com/gp/product/B003M5H15C

This Month in CHEST: Editor’s Picks

BY DR RICHARD S. IRWIN, MASTER FCCP
Editor in Chief, CHEST

Factors Associated With Illness Perception Among Critically Ill Patients and Survivors
By Dr D. Ford, FCCP, et al.

Risk of COPD From Exposure to Biomass Smoke: A Metaanalysis
By Dr G. Hu, et al.

CHEST Abstracts Delivered To You. Wherever You Are.

Monthly CHEST Current Issue abstracts and weekly CHEST Papers in Press abstracts are now available for delivery to your Kindle™ e-reader.

Current Issue feed provides the table of contents list and abstracts ahead of the print issue. Papers in Press feed offers weekly access to the abstracts of just-accepted original research to be published in CHEST. Full-text articles not available.

Try it free for 2 weeks. Subscribe for a $1.99 monthly fee (per feed).

Current Issue: www.amazon.com/gp/product/B003MSH184
Papers in Press: www.amazon.com/gp/product/B003M5H15C

This Month in CHEST: Editor’s Picks

BY DR RICHARD S. IRWIN, MASTER FCCP
Editor in Chief, CHEST

Factors Associated With Illness Perception Among Critically Ill Patients and Survivors
By Dr D. Ford, FCCP, et al.
Top 5 Things To Do in Vancouver

Looking for ideas on what to do while in Vancouver for CHEST 2010? How about some recommendations from a local resident? Meet Dr. Frank Ervin. Dr. Ervin is Clinical Instructor, Department of Medicine, University of British Columbia, and Respirologist, Ridge Meadows Hospital, Maple Ridge, BC, Canada.

Having lived in Vancouver and Maple Ridge for 23 years, he knows the area well and recently shared recommendations for what to do during your stay in Vancouver.

1. Ride the Skytrain to Surrey on the Expo line, and return via the Millennium Line.

   The Skytrain offers an area tour for a song, and the system isn’t crowded during off-peak hours. Buy a day pass from Translink for the trip. Stop off at the New Westminster Quay “Rivermarket,” and walk along the boardwalk, observing the busy river traffic on the Fraser River. I love the New Westminster waterfront area for its vistas and people watching (www.translink.ca).

2. Take a sightseeing flight on a float plane from the Vancouver Harbor.

   You won’t believe the beauty of the area from the air, and a float plane experience is great fun in itself (www.harbourair.com/tours.php).

3. Fly on a float plane to Victoria.

   Visit beautiful Victoria, including the Royal British Columbia Museum, or take a side trip to the lovely Butchart Gardens.

4. Return to Vancouver on the BC Ferries system, and then catch the Pacific Coach Lines bus on the ferry or in Victoria to return to downtown Vancouver (www.harbourair.com/HA%20Map_0207.pdf).

5. Spend an evening at the Arts Club Theatre Company. Playing during CHEST 2010 is “The 39 Steps.” Hitchcock meets hilarious in this spoof, which features a seductive mystery woman, an accusation of murder, a missing finger, and a mad dash to foil foreign spies!

Four gifted actors play more than 150 zany characters in this Monty Python-flavored Hitchcock spoof that just might give you a case of vertigo! (www.artsc locus.com/index.html)

6. Listen to the Vancouver Symphony Orchestra.

   During CHEST 2010, the Vancouver Symphony Orchestra will present Musically Speaking 1, an evening of music by English composers, including works by Sir Edward Elgar and Ralph Vaughan Williams.

   Be sure to buy your tickets online to avoid disappointment! (www.vancouversymphony.ca)

   Don’t miss CHEST 2010, October 30 - November 4, in Vancouver. Recognized around the world as the authority in clinical chest medicine, CHEST 2010 will feature an essential learning program in pulmonary, critical care, and sleep medicine.

   To learn more about CHEST 2010, visit www.accpmeeting.org.

Enrollment for EHR Program Available Online

The Centers for Medicare & Medicaid Services (CMS) has established an Internet-based Provider Enrollment, Chain and Ownership System (PECOS) as an alternative to the paper (CMS-855) enrollment process. Internet-based PECOS will allow physicians, nonphysician practitioners, and provider and supplier organizations to enroll, make a change in their Medicare enrollment, view their Medicare enrollment information on file with Medicare, or check on the status of a Medicare enrollment application. The American Recovery and Reinvestment Act of 2009 authorized CMS to provide incentive payments for the “meaningful use” of certified electronic health record (EHR) technology.

For more information about the Internet-based PECOS, select the “Internet-based PECOS” link to the left on the CMS Web site at www.cms.hhs.gov/MedicareProviderSupEnroll; and for additional information, click on “Tips to Facilitate the Medicare Enrollment Process” under “Downloads.” If you enrolled in Medicare after November 2003, or have updated Medicare enrollment information since then, you do not need to take further action. To verify your enrollment record in PECOS, go to www.cms.gov/MedicareProviderSupEnroll.

ACCP Board Review.
The Proven Leader in Comprehensive Review Programs

Prepare for board certification examinations with comprehensive review programs from the proven leader in board review curricula. Only the ACCP offers:

- Board-exam-focused programs, emphasizing the same content areas as the ABIM.
- Presentations that include lectures, self-assessment opportunities, and smaller tutorial sessions focusing on key topics.
- Assessment tools to measure your exam readiness and guide your study preparation.

NEW! Early Access to Course e-Books

Tuition includes free online access to the course e-book.

- Navigate content with a user-friendly format.
- Find topics with advanced search capabilities.
- Link to referenced articles.

Access to the pulmonary, critical care, and sleep medicine e-books will be available upon registration. Access to the pediatric pulmonary medicine e-book will be available approximately 2 weeks prior to the course. (You will be given access only to the e-book(s) corresponding to the course(s) for which you register.)

Register Today

www.chestnet.org
(800) 343-2227 or (847) 498-1400

- Register by August 5 for an early registration discount.
- Register online for two review courses, and receive 15% off the combined tuition (online offer only).
- Registration forms also available for download at www.chestnet.org.
Cardiovascular Medicine and Surgery

The ROOBY trial was a large (2,203 patients), controlled, randomized, multicenter, VA cooperative study that evaluated the efficacy of on-pump vs off-pump coronary artery bypass grafting (CABG). Patients underwent a coronary angiogram at 1 year post-CABG. The main findings were published in the *New England Journal of Medicine* (Shroyer et al. *N Engl J Med*. 2009;361[19]:1827).

The primary short-term composite endpoint included death or major complications (reoperations, cardiac arrest, new mechanical support, stroke, or renal failure requiring dialysis) occurring within 30 days postoperatively or before hospital discharge. The primary long-term composite endpoint was death, nonfatal myocardial infarction, and repeat revascularization within 1 year. Secondary endpoints included completeness of revascularization, graft patency, and neuropsychological outcome.

Short-term primary endpoints for both groups were similar (7% off-pump vs 9% on-pump). Mortality was 1.6% and 1.2% for off-pump and on-pump patients, respectively. As a whole, the off-pump group had a higher long-term primary composite endpoint (9.9% vs 7.4%), more deaths from cardiac causes (2.7% vs 1.3%), higher incomplete revascularization rate (11.1% vs 7.8%), and lower 1-year graft patency (82.6% vs 87.8%) than the on-pump group. The patency for left internal thoracic artery grafted to the left anterior descending artery was similar between the groups (off-pump 95.3% vs on-pump 96.2%). Long-term composite changes in individual neuropsychological test scores were similar or improved from baseline for both groups.

The ROOBY trial is the first large study showing no differences in short-term primary endpoints between the off-pump and on-pump procedures. The long-term endpoint favored the on-pump patients for death or graft patency. The patency rate for internal thoracic artery graft was similar for both groups. No difference in neurocognitive dysfunction was observed between the use of pump and no pump. Both treatment groups showed improved neurocognitive function at 1 year.

**Dr G. Hossein Almassi, FCCP**
**Steering Committee Member**

**Chest Infections**

**Antibiotic Development: Many Challenges, Few Solutions**

Antibiotic-resistant bacteria are responsible for an increasing number of infections in the hospital and community settings, while the number of antibiotics is decreasing. The Infectious Diseases Society of America (IDSA) has launched “10×20,” an initiative to advocate for a global antibiotic development by 2030. The main findings were published in the *New England Journal of Medicine* (Shroyer et al. *N Engl J Med*. 2009;361[19]:1827).

The primary short-term composite endpoint included death or major complications (reoperations, cardiac arrest, new mechanical support, stroke, or renal failure requiring dialysis) occurring within 30 days postoperatively or before hospital discharge. The primary long-term composite endpoint was death, nonfatal myocardial infarction, and repeat revascularization within 1 year. Secondary endpoints included completeness of revascularization, graft patency, and neuropsychological outcome.

Short-term primary endpoints for both groups were similar (7% off-pump vs 9% on-pump). Mortality was 1.6% and 1.2% for off-pump and on-pump patients, respectively. As a whole, the off-pump group had a higher long-term primary composite endpoint (9.9% vs 7.4%), more deaths from cardiac causes (2.7% vs 1.3%), higher incomplete revascularization rate (11.1% vs 7.8%), and lower 1-year graft patency (82.6% vs 87.8%) than the on-pump group. The patency for left internal thoracic artery grafted to the left anterior descending artery was similar between the groups (off-pump 95.3% vs on-pump 96.2%). Long-term composite changes in individual neuropsychological test scores were similar or improved from baseline for both groups.

The ROOBY trial is the first large study showing no differences in short-term primary endpoints between the off-pump and on-pump procedures. The long-term endpoint favored the on-pump patients for death or graft patency. The patency rate for internal thoracic artery graft was similar for both groups. No difference in neurocognitive dysfunction was observed between the use of pump and no pump. Both treatment groups showed improved neurocognitive function at 1 year.

**Dr G. Hossein Almassi, FCCP**
**Steering Committee Member**

**Clinical Pulmonary Medicine**

**Lung Disease in the Elderly**

The US Census Bureau estimates that by 2015, 15% of the US population will be over age 65. As the population ages, it will be important to understand the relationship between aging and lung disease. Dyspnea or dyspnea on exertion is a common complaint of the elderly, but it is also common for older people to attribute dyspnea to the natural process of aging and not report it. It is important for pulmonologists to recognize that dyspnea is underreported and make a special effort to elicit this symptom through patient questionnaires or assessment. Cardiac and respiratory disease are the most common causes of shortness of breath in the elderly and often present as comorbidities, making the diagnosis much more difficult. Studies in normal nonmoking elderly subjects demonstrate that there is reduced lung elastic recoil, reduced chest wall compliance, and a decrease in respiratory muscle strength. These changes result in a decline in the FEV1, the FVC, and the FEV1/FVC ratio with aging. The total lung capacity (TLC) is not changed with age, but the residual volume (RV) does increase, resulting in an increase in the RV to TLC ratio over time. All of these changes can result in the overdiagnosis of airflow limitation in the elderly. And some researchers suggest that the elderly are less responsive to bronchodilators. The symptom of dyspnea must be explored in detail, and lung function studies must be interpreted using “age-ized” lower limits of normal, not percent predicted. In the acutely dyspneic elderly, the differential is large and requires a systematic approach to rule out life-threatening cardiopulmonary disorders. Because older patients have multiple comorbidities and there is underreporting of dyspnea by the elderly, these patients present a diagnostic challenge to the pulmonologist.

**Dr Craig Papette, FCCP**
**Steering Committee Member**

**Disaster Response**

**Haiti Retrospective**

It has been more than 4 months since the Haiti earthquake, and I follow the drama there now as the crisis continues. With the retrospective on high and with input from many who continue to stay involved in the clinical care on the ground, we can see patterns develop. Specifically, three aspects have emerged that challenge the way forward for the small island country.

- Mass mortality and internal displacement of the population. New “cities” now emerge from displaced people who are attempting to set up infrastructure in what were intended as temporary centers. These have no assistance in planning, lack basic public health infrastructure, and have rudimentary local governmental control. Such circumstances invite the onslaught of vector-borne diseases, with resulting outbreaks of dengue and chikungunya extending outward from the camps.
- The capability. Not only did Haiti lose its trained medical providers, but a dual end-0th and vaccine responder antigens, or placebo (n=209) over a 52-week period. The primary endpoint was time to progression of disease or death. Secondary endpoints included quality-of-life measures and change in pulmonary function studies.

Investigators found no significant differences between groups with respect to the primary or secondary endpoints. Subgroup analyses similarly failed to achieve the prespecified endpoints. Patients receiving bosentan had a significantly increased rate of elevated liver function studies results compared with the placebo group. The investigators concluded that bosentan was no different than placebo in this trial.

The second study was a randomized, double-blind, placebo-controlled study of 180 patients with advanced IPF. See the report on p. 3 of this issue for more details.

Two additional clinical trials, sponsored by the NHLBI-funded IPF Clinical Research Network, are now enrolling patients. PANTHER-IPF (ClinicalTrials.gov identifier NCT00660991) is a randomized, double-blind study evaluating prednisone, azathioprine, and N-acetylcysteine vs N-acetylcysteine vs placebo in IPF, while ACE-IPF (ClinicalTrials.gov identifier NCT00972424) is examining the efficacy of anticoagulation with warfarin vs placebo in patients with IPF.

**Dr Imre Neth, FCCP, NetWork Chair; and Dr Eric S. White, FCCP, NetWork Member**

**Tobacco Dependence Treatment Toolkit**

Darlene Buczak Award for Innovations in Education

BY DR BRIAN CARLIN, FCCP

The Darlene Buczak Award for Innovations in Education was established by the Association of Pulmonary and Critical Care Medicine Program Directors in 2009 to honor Ms. Buczak’s service to the organization. This award is given to an individual who demonstrates excellence and innovation in the education of pulmonary and critical care medicine fellows. The award is given on a yearly basis.

Dr Jennifer McCallister, Associate Fellowship Director for the Ohio State University pulmonary and critical care medicine training program, was the first recipient of the award. Dr McCallister has developed a month-long immersion curriculum that is delivered to all incoming first-year fellows during the month of July. The curriculum is designed to establish minimum cognitive and procedural competencies in key topics and procedures in the field prior to the new fellow beginning actual patient care responsibilities.

In the program, lectures and computer-based lessons are used to review relevant basic physiology, core clinical topics, and essential procedures. Technical skills and baseline procedural competencies are established through the use of simulators, cadaver laboratories, direct faculty instruction, and wet labs. Competency is assessed through a written pretest and posttest and direct observation of skills by faculty members. The curriculum is in its third year and has been well received by both fellows and faculty.

Dr Laura Evans, Associate Fellowship Director for the New York University pulmonary and critical care medicine training program, was this year’s recipient of the award. Dr Evans has developed a structured research curriculum for fellows in an attempt to improve the career development process. This curriculum has been in place for the last 2 years and is started during the first year of the training program.

First-year fellows attend a 2-day “research retreat” to learn about ongoing research activities, meet the research faculty, and receive an overview of possible pathways toward an academic career. Each fellow is then expected to meet with potential research mentors over the ensuing months and to choose a research project. At the beginning of their second year in training, a series of research methodology lecture courses is given. The curriculum has been perceived to be beneficial from both the faculty and fellow perspectives.

Assessment of competency of cognitive and procedural skills and development of clinician scientists are just two of many aspects of training that are essential to the education of pulmonary and critical care fellows. Drs. McAllister and Evans have developed innovative methods to address these two issues, with positive outcomes. These two projects show the innovations in education and training that form the basis for the Darlene Buczak award.

3rd Annual Case Competition Addressed Diabetes

The CHEST Foundation, the philanthropic arm of the American College of Chest Physicians (ACCP), the Social Enterprise at Kellogg (SEEK) of the Kellogg School of Management, the Carol and Larry Levy Social Entrepreneurship Lab; and Medtronic Diabetes sponsored the 3rd Annual Case Competition that held its culmination dinner on May 11, 2010. Participants of this year’s competition included the Centers for Disease Control and Prevention (CDC) Foundation and the American Diabetes Association (ADA).

The 2010 case competition addressed the growing epidemic of diabetes in the United States. Professor Timothy Feddersen, Wendell Hobs Professor of Managerial Politics and Director of SEEK, Kellogg School of Management, and Jamie N. Jones, PhD, Assistant Director of Social Enterprise and the Carol and Larry Levy Social Entrepreneurship Lab at Kellogg, challenged the teams to devise viable business models that would link care providers, patients, and community resources in the successful treatment of diabetes. Six student teams from the Kellogg School of Management and the Feinberg School of Medicine developed sustainable business solutions that focused on providing innovative diabetes care models.

As in the previous 2 years, the case competition secured the expert assistance of members of the medical, community, and business realms to work as advisors with the six competing teams. National leaders from the business, government, and philanthropic sectors served as preliminary reviewers and final judges.

This year’s preliminary judges were Dr John C. Alexander Jr, FCCP, President, The CHEST Foundation, and Head of Cardiac Surgery, NorthShore University Health System; Robert F. Barnett III, Board Member, The CHEST Foundation, and Financial Advisor, WeaCap Advisors; Jeffrey C. Bauer, PhD, Partner, Management Consulting Futures Practice, ACS Healthcare Solutions; David Dranove, Walter J. McNerney Professor of Health Industry Management and Director of Health Enterprise Management at Kellogg; Professor Tim Feddersen; Dr Allen I. Goldberg, Master FCCP, Past President, ACCP, Jamie N. Jones, PhD, Marilyn A. Lederer, CPA, Executive Director, The CHEST Foundation; and Sanggeeta Vohra, Associate Director of The Center for Biotechnology at Kellogg.

These judges reviewed the six cases to determine which two teams would present to the distinguished panel of judges at the culmination dinner.

Final round judges included Christine Beebe, Associate Director, Takeda Pharmaceuticals North America, Inc; and Incoming Chair of the Board for the ADA-Chicago Chapter; Thomas Haggerly, President, Institute of Allied Medical Professions; Greg Kapust, CEO, Breathe Technologies; Rachel Lieberman, Director of Programs, ADA-Chicago Chapter; John Moore, PhD, RN, Chronic Disease Director’s Office, CDC, and Leo Mullin, Chairman of the Board, Juvenile Diabetes Research Fund, and Senior Advisor, Goldman Sachs Capital Partners.

The two finalist teams—Ticket To Change—a field trip that presented their business plans at the dinner. Dia-life team members Harold Hsiung, Will Liu, Milind Kopikare, Amy Ide, Mihir Naware, and Jennifer McCallister, Associate Fellowship Director for the Ohio State University pulmonary and critical care medicine training program, won the award.

Professor Tim Feddersen and Dr John Alexander pose with the 2010 Kellogg Case Competition winning team, Dia-life. Team members (L-R): Harold Hsiung, Aji Thupil, Mihir Naware, Amy Ide, Milind Kopikare, and Will Liu.
PROFESSIONAL OPPORTUNITIES

West Coast
INVASIVE AND NON-INVASIVE CARDIOLOGY, CRITICAL CARE, HOSPITALIST & INTERNAL MEDICINE, & PULMONOLOGY OPPORTUNITIES
Northern, Central & Southern California, The Pacific Northwest & Hawaii

Learn More
Visit www.adventisthealth.org/phyjobs or contact Physician Recruiter Ryan Rasmussen at 800.847.9840 or phyjobs@ah.org.

ADVANTAGEOUS HEALTHCARE SYSTEM
With strong base in all critical care specialties: ICU, Cardiac, CVICU, NeuroICU, Trauma. Impacting lives and shaping the care of critically ill patients in our Intensive Care Unit.

Forbes and Fortune Small Business Magazine rank Billings, Montana - the Best!
Practice medicine in a city ranked as one of the Best Small Places for Business and Careers (Forbes, 2009) and the Best Small City in which to start a business (Fortune Small Business Magazine, November 2009).
St. Vincent Healthcare in Billings, Montana seeks a well-trained, compassionate physician for Pulmonology and Critical Care Medicine
• Great practice with maximum flexibility that focuses on quality lifestyle
• Full time or part time position available
• ICU service Call: 1-4
• Outpatient Pulmonology clinic: low overhead practice
• Hospitalist program available
• Pediatric Intensive Care Unit staffed 24/7 with Board Certified Pediatric Intensivists
• SVH is staffed for 250 beds
• Regional destination hospital: serves a four-state area and more than 900,000 people each year
• AASM accredited sleep center; Level II Trauma Center; HELP Helicopter and Fixed Wing air transport program with specialty transport teams
• SVH invests in the latest technology
• SVH is ranked Best for Heart Attack Care and #15 for Quality in the nation
• Thriving medical community in a family-oriented suburban location
• Excellent School System
• Abundant recreational activities year round – hiking, skiing, fishing, biking and camping
• Excellent Benefits and Competitive Salary Structure, based on MGMA
• Sign-on Incentives, Moving Allowances, and CME reimbursement

Contact: Colleen Martin at Colleen.Martin@svh.mt.org or 406-237-4003

Chest Physician assumes the statements made in classified advertisements are accurate, but cannot investigate the statements and assumes no responsibility or liability concerning their content. The Publisher reserves the right to decline, withdraw, or edit advertisements. Every effort will be made to avoid mistakes, but responsibility cannot be accepted for clerical or printer errors.
SOME WARRIORS DON’T WEAR ARMOR.

Lead the fight to save lives, and change the future with Methodist.

Critical Care Physician/Intensivist Opportunity

The Division of Critical Care Medicine in the Department of Medicine at The Methodist Hospital Physician Organization, Houston, TX, a renowned top-ranked organization, is recruiting intensivist physicians for its medical intensive care unit patients. The ICUs are collaborative partnerships with physicians, mid level providers (nurse practitioners and physician assistants) and ancillary staff. Successful candidates will perform critical care duties and have teaching responsibilities. Care is provided through 24 hour faculty coverage on a shift schedule. Applicants will be expected to be Board certified or eligible in critical care. A highly competitive salary and comprehensive benefits package are available.

The Methodist Hospital, located at the Texas Medical Center, provides a rich environment of world-class biomedical science, innovative medical education and a dedication to the highest quality patient care. The Methodist Hospital is proud of its partnerships with the Weill Medical College of Cornell University and New York-Presbyterian Hospital. This extraordinary cross-country collaboration among three of our country’s leading health care institutions is the first of its kind. This marks a new approach for furthering our shared missions of excellence in patient care, research and teaching.

To join the team led by Janice Zimmerman, M.D., Division Head, Critical Care Medicine, please email your letters of interest and CVs to Tidy Hicks, Human Resource Director, The Methodist Hospital at TIDHicks@tmhhs.org.

Acute Care Nurse Practitioner - MICU

$5,000 Sign-On Bonus * 12-Hour Shifts, Nights

As part of The Methodist Hospital Physician Organization (TMHPO), you must have ER or ICU experience, a Masters degree in Nursing and three (3) years of clinical nursing experience (prefer two years in Advanced Practice role). In addition, you must be a Texas-licensed RN and credentialed as an Advanced Practice Nurse, and have prescriptive authority privileges through the State. ACNP certification essential. Additional openings are available with The Methodist Hospital.

TMHPO is an integral part of The Methodist Hospital’s overall strategy to become one of the nation’s leading academic medical centers. TMHPO enables physicians to maintain autonomy with respect to their clinical practice while growing their practice within an academic environment.

For consideration, please apply online at methodisthealth.com/careers, Search TMH Physician Organization, Category: Nurse Practitioner; Apply to Req#: meth-0038631.

YOU SEE YOURSELF AS A LEADER, we see you at Methodist.

Methodist® The Methodist Hospital
Physician Organization®

Houston, Texas

LEADING MEDICINE®

An Equal Opportunity Employer.

The Methodist Hospital System is the official health care provider of the Houston Texans, Houston Astros, Houston Dynamo, Rice Athletics, Houston Ballet, Houston Grand Opera and Houston Symphony.

GIVE

DONATE TODAY!

www.chestfoundation.org

To The AMERICAN CANCER SOCIETY

Let’s not pollute our ocean of air

like we polluted theirs.

Poisoned air can shorten life with every breath. Only with your help can we stem the tide.

It’s a matter of life and breath.

AMERICAN LUNG ASSOCIATION®

The Christmas Seal People®

Spa courtesy of the publisher and its partners.
Unparalleled Visualization and Guidance

LungPoint® Virtual Bronchoscopic Navigation highlights the path as you maneuver through airways and guides you directly to your target. Navigate quickly and accurately without proprietary hardware or expensive disposable catheters.

LungPoint Systems are easy to use and affordable. Call today for a hands-on demonstration of LungPoint® VBN – The leading virtual navigation solution, or get started with LungPoint® Planning – The most sophisticated stand-alone planning and virtual guidance solution.

Call or email today:
1-877-428-1600
sales@broncus.com
www.broncus.com